Parkinson

Parkinson

Neurochirurgie
Ultrasone therapie voor de ziekte van Parkinson
De behandeling van de novo patiënten met de ziekte van Parkinson begint met niet-medicamenteuze bewegingstherapie. De volgende stap in het behandelplan is het geven van medicijnen; eerste keus is Levodopa (L-DOPA) medicatie. Nadeel van dit type medicatie is dat het een verhoogd risico op dyskinesieën geeft. De medicijnen zijn na verloop van tijd ook minder […]
Neurologie

Parkinson nieuws

Nigrostriatal blood-brain barrier opening in Parkinsons disease
jnnp.bmj.com
The nigrostriatal system is especially vulnerable to neurodegeneration in Parkinson’s disease (PD) and the blood-brain barrier (BBB) is a limiting factor for delivery of therapeutic agents to the br...
[Corrections] Correction to Lancet Neurol 2024; 23: 465–76
thelancet.com
Espay AJ, Stocchi F, Pahwa R, et al. Safety and efficacy of continuous subcutaneous levodopa–carbidopa infusion (ND0612) for Parkinson's disease with motor fluctuations (BouNDless): a phase 3, randomised, double-blind, double-dummy, multicentre trial. Lancet Neurol 2024; 23: 465–76—In this Article, the BouNDless Study Group has been updated. This correction has been made to the online version as of May 15, 2024.
Marked laterality of olivopontocerebellar pathology in an autopsied patient with MSA: Implications for degeneration and {alpha}-synuclein propagation
jnnp.bmj.com
Multiple system atrophy (MSA) is a sporadic adult-onset neurodegenerative disorder characterised by autonomic dysfunction, cerebellar ataxia and parkinsonism, each due to degeneration of the autonomic...

Log in met Medi-Access om meer nieuws te zien

Inloggen Aanmelden